Authors

Latest:

Dr. Jochelson on the Limitations of Mammography and Ultrasound in Screening for Breast Cancer

Maxine S. Jochelson, MD, discusses the limitations of mammography and ultrasound in screening patients for breast cancer.

Maya E. Guglin, MD, PhD

Latest:

Preventing Chemotherapy-Induced Cardiomyopathy: Can We? Should We?

Anthracyclines widely used for a variety of malignancies cause cardiotoxic effects that manifest as cardiomyopathy. Maya E. Guglin, MD, PhD, discusses supportive therapy for these patients.

Mayer Fishman, MD, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Mazyar Shadman, MD, MPH

Latest:

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

Dr Shadman discusses key findings and implications from trials that were presented at the 2024 ASH Annual Meeting investigating zanubrutinib in CLL.

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center

Latest:

A Phase 2 Study of Zanubrutinib in Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib: Preliminary Results for Patients With CLL/SLL

Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.

McKesson Specialty Health

Latest:

Saving Time, Money, and Trouble With an Inventory Management Upgrade

Changes in cancer care, regulations, and reimbursement create more pressure on practices than ever before to improve care, reduce costs, and remain viable in an atmosphere of mergers and acquisitions.

Latest:

PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck Radiation

A feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.

MD Anderson Cancer Center

Latest:

MD Anderson Launches Institute for Cell Therapy Discovery & Innovation to Deliver Transformational New Therapies

The institute builds upon institutional expertise to develop and advance impactful cell therapies for cancer, autoimmune conditions and infections.

MDNG Editors

Latest:

20 Best Health 2.0 Tools for Physicians and Patients

The premise of Health 2.0 rests on one simple idea: whatever your healthcare question or concern may be, there is a potential community of likeminded individuals out there who are ready and willing to share.

Meadow Green

Latest:

Value and Market Access Considerations Often Missing From Trial Design

Having an evidence package at launch that satisfies payersâ€™ value criteria will increase the likelihood that payers will reimburse the drug at a desirable price and enable patient access to innovative treatments.

Medical Center

Meena Savur Moran, MD

Latest:

Dr. Moran on Techniques to Decrease Toxicities With Radiation in Breast Cancer

Meena Savur Moran, MD, radiation oncologist, professor, Therapeutic Radiology, director, Breast Cancer Radiotherapy Program, Yale Cancer Center, discusses some of the techniques that oncologists can use to decrease the toxicities associated with radiation therapy when treating patients with breast cancer.

Megan E. Daly, MD

Latest:

Dr. Daly on Clinical Trials With Radiation Therapy in Lung Cancer

Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.

Megan Garlapow, PhD

Latest:

Immunotherapy Continues to Advance in Head and Neck Cancer

An early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.

Megan Kruse, MD, of Cleveland Clinic

Latest:

Clinical Benefits With Neratinib in HER2+ Early Breast Cancer

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.

Mehmet Asim Bilen, MD, Emory University School of Medicine

Latest:

Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

The panel discusses the best approaches to treating patients with non-clear cell RCC.

Mehmet Sitki Copur, MD

Latest:

The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Mehmood Hashmi, MD

Latest:

Dr. Hashmi on Immunotherapy in Prostate Cancer

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

Meir Rinde

Latest:

Fixed-Duration Therapy Struggles to Find Footing Across Tumor Types

Fixed-duration systemic therapies have gained some traction in hematologic malignancies, where advances in drug development and sequencing strategies have afforded investigators the opportunity to conduct trials.

Meir Wetzler, MD

Latest:

Novel Therapies for T315I-Mutant Chronic Myeloid Leukemia

Abelson tyrosine kinase (ABL1) is a nonreceptor tyrosine kinase involved in cell growth and proliferation.